Publication | Closed Access
Fluorine and Nitrogen Co-Doped Carbon Dot Complexation with Fe(III) as a <i>T</i><sub>1</sub> Contrast Agent for Magnetic Resonance Imaging
50
Citations
52
References
2019
Year
Commercial gadolinium-based materials have been widely used as contrast agents for magnetic resonance imaging (MRI), but the high toxicity of leaking free Gd<sup>3+</sup> ions still raises biosafety concerns. Here, we develop a novel, safe, and efficient MRI contrast agent based on a stable Fe(III) complex of fluorine and nitrogen co-doped carbon dots (F,N-CDs) that was prepared from glucose and levofloxacin by a simple microwave-assisted thermal decomposition method. The obtained Fe<sup>3+</sup>@F,N-CD complex exhibits higher longitudinal relaxivity ( r<sub>1</sub> = 5.79 mM<sup>-1</sup>·s<sup>-1</sup>) than that of the control samples of the Fe<sup>3+</sup>@CD complex ( r<sub>1</sub> = 4.23 mM<sup>-1</sup> s<sup>-1</sup>) and free Fe<sup>3+</sup> ( r<sub>1</sub> = 1.59 mM<sup>-1</sup> s<sup>-1</sup>) in aqueous solution, as assessed by a 1.5 T NMR analyzer. More importantly, the Fe<sup>3+</sup>@F,N-CD complex is very stable with a large coordination constant of 1.06 × 10<sup>7</sup> in aqueous medium. While incubated with HeLa cells, the Fe<sup>3+</sup>@F,N-CD complex shows clear MR images, demonstrating that it has potential to be an excellent MRI contrast agent. Furthermore, in vivo MRI experiments indicate that the Fe<sup>3+</sup>@F,N-CD complex provides high-resolution MRI pictures of 4T1 tumor bearing BALB/c mice 15 min after injection and can be completely excreted 2 h after administration. No cytotoxicity was observed with F,N-CDs and Fe concentration up to 0.2 mg/mL and 0.3 mM in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell proliferation assay, respectively. The possible mechanism of the enhanced MRI effect of the Fe<sup>3+</sup>@F,N-CD complex is therefore proposed. The extremely low toxicity, high r<sub>1</sub> relaxivity, strong photoluminescence, and low synthetic cost enable the Fe<sup>3+</sup>@F,N-CD complex to be a safe and promising T<sub>1</sub>-weighted MRI contrast agent for clinical applications.
| Year | Citations | |
|---|---|---|
2013 | 3.6K | |
2012 | 2.7K | |
2009 | 1.8K | |
2006 | 1.1K | |
2011 | 937 | |
2014 | 931 | |
2014 | 635 | |
2016 | 507 | |
2018 | 498 | |
2017 | 463 |
Page 1
Page 1